AcelRx Pharma (ACRX) Tops Q2 EPS by 6c

AcelRx Pharma (NASDAQ: ACRX) reported Q2 EPS of ($0.16), $0.06 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $608 thousand versus the consensus estimate of $960 thousand.

For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79